U.S. Department of Health & Human Services
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report
Institute for Clinical and Economic Review, issuing body. New England Comparative Effectiveness Public Advisory Council, issuing body.
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Immunologic Factors -- therapeutic use
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license.
1 online resource (1 PDF file (various pagings))
NLM Unique ID:
See catalog record
Metadata (Dublin Core)